Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells

Neoplasma

Volumn 62, Issue 4, 2015, Pages 574-581

  Ruan, Y ^a   Huang, S ^a   He, D ^b   Gopaul, R ^a   Li, Z ^a   Chen, G ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Glioma; Neutralization antibody; Proliferation; TNFRSF6B

Indexed keywords

DECOY RECEPTOR 3; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CASPASE ASSAY; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84943634471     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_069     Document Type: Article

References (24)

1. Kovar JL, Curtis E, Othman SF, Simpson MA, Olive DM. Characterization of IRDye 800CW chlo­rotoxin as a targeting agent for brain tumors. Analytical biochemistry 2013, 440: 212-219. http://dx.doi.org/10.1016/j.ab.2013.05.013
2. Kao HW, Chiang SW, Chung HW, Tsai FY, Chen CY. Advanced MR imaging of gliomas: an update. BioMed research international 2013, 2013: 970586.
3. Chang L, Su J, Jia X, Ren H. Treating malignant glioma in Chinese patients: update on temozolomide. OncoTargets and therapy 2014, 7: 235-244.
4. Wang YX, Fan K, Tao DB, Dong X. Association between genetic polymorphism of xrcc1 gene and risk of Glioma in a Chinese population. Asian Pacific journal of cancer preven­tion: APJCP 2013, 14: 5957-5960.
5. Choi J, Lee EY, Shin KJ, Minn YK, Kim J, et al. IDH1 mutation analysis in low cellularity specimen: a limitation of diagnostic accuracy and a proposal for the diagnostic proce­dure. Pathology, research and practice 2013, 209: 284-290. http://dx.doi.org/10.1016/j.prp.2013.02.010
6. Morishige T, Yoshioka Y, Inakura H, Tanabe A, Yao X, et al. Creation of a lysine-deficient LIGHT mu­tant with the capacity for site-specific PEGylation and low affinity for a decoy receptor. Biochemical and biophysical research communications 2010, 393: 888-893. http://dx.doi.org/10.1016/j.bbrc.2010.02.119
7. Connor JP, Felder M, Kapur A, Onujiogu N. DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with correspond­ing alteration in the expression of BRCA1. BMC cancer 2012, 12: 176. http://dx.doi.org/10.1186/1471-2407-12-176
8. Wang W, Zhang M, Sun W, Yang S, Su Y, et al. Re­duction of Decoy Receptor 3 Enhances TRAIL-Mediated Apoptosis in Pancreatic Cancer. PloS one 2013, 8: e74272. http://dx.doi.org/10.1371/journal.pone.0074272
9. Yang D, Fan X, Yin P, Wen Q, Yan F, et al. Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer. BMC immunology 2012, 13: 28. http://dx.doi.org/10.1186/1471-2172-13-28
10. Chen G, Luo D. Expression of decoy receptor 3 in liver tis­sue microarrays. The National medical journal of India 2008, 21: 275-278.
11. Chen G, Luo D. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Upsala jour­nal of medical sciences 2008, 113: 297-304. http://dx.doi.org/10.3109/2000-1967-240
12. Chen G, Rong M, Luo D. TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathology, research and practice 2010, 206: 631-641. http://dx.doi.org/10.1016/j.prp.2010.05.011
13. Yang M, Chen G, Dang Y, Luo D. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Upsala journal of medical sciences 2010, 115: 232-237. http://dx.doi.org/10.3109/03009734.2010.516410
14. Huang S, Chen G, Dang Y, Chen LH. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. TheScientificWorldJournal 2014, 2014: 605236.
15. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, et al. Soluble decoy receptor 3 is expressed by malig­nant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer research 2001, 61: 2759-2765.
16. Arakawa Y, Tachibana O, Hasegawa M, Miya­mori T, Yamashita J, et al. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta neuropathologica 2005, 109: 294-298. http://dx.doi.org/10.1007/s00401-004-0956-6
17. Xin YH, Bian BS, Yang XJ, Cui W, Cui HJ, et al. POU5F1 enhances the invasiveness of cancer stem-like cells in lung adenocarcinoma by upregulation of MMP-2 expression. PloS one 2013, 8: e83373. http://dx.doi.org/10.1371/journal.pone.0083373
18. Gou X, Chen H, Jin F, Wu W, Li Y, et al. Expressions of CD147, MMP-2 and MMP-9 in Laryngeal Carcinoma and its Correlation with Poor Prognosis. Pathology oncology research 2014, 20: 475-481. http://dx.doi.org/10.1007/s12253-013-9720-3
19. Ao R, Du YQ, Wang Y, Chen YS, Wang BY. MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival. International journal of clinical and experimental medicine 2013, 6: 700-705.
20. Jacob-Ferreira AL, Kondo MY, Baral PK, James MN, Holt A, et al. Phosphorylation status of 72 kDa MMP-2 determines its structure and activity in response to perox­ynitrite. PloS one 2013, 8: e71794. http://dx.doi.org/10.1371/journal.pone.0071794
21. Seo KW, Lee SJ, Kim YH, Bae JU, Park SY, et al. Mechani­cal stretch increases MMP-2 production in vascular smooth muscle cells via activation of PDGFR-beta/Akt signaling pathway. PloS one 2013, 8: e70437. http://dx.doi.org/10.1371/journal.pone.0070437
22. Korkmaz KS, deRooij BJ, vanHoek B, Janse M, Coenraad MJ, et al. MMP-2 is a disease-modifying gene in primary sclerosing cholangitis. Liver international: official journal of the International Association for the Study of the Liver 2014, 34: 274-280.
23. Lee H, Chang KW, Yang HY, Lin PW, Chen SU, et al. MT1-MMP regulates MMP-2 expression and angiogenesis-related functions in human umbilical vein endothelial cells. Biochemical and biophysical research communications 2013, 437: 232-238. http://dx.doi.org/10.1016/j.bbrc.2013.06.046
24. Wu HM, Wang HS, Huang HY, Lai CH, Lee CL, et al. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metallopro­teinase (MMP)-2. BMC cancer 2013, 13: 300. http://dx.doi.org/10.1186/1471-2407-13-300